Cellular Anti-Seizure Mechanisms of Everolimus in Pediatric Tuberous Sclerosis Complex, Cortical Dysplasia, and Non-mTOR-Mediated Etiologies

Epilepsia Open - United States
doi 10.1002/epi4.12253
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Wiley

Related search

Altered Inhibition in Tuberous Sclerosis and Type IIb Cortical Dysplasia

Annals of Neurology
Neurology
2012English

mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia

Journal of Neuroscience
Neuroscience
2019English

Differential Cellular Expression of Neurotrophins in Cortical Tubers of the Tuberous Sclerosis Complex

American Journal of Pathology
Forensic MedicinePathology
2001English

A Randomized Controlled Trial With Everolimus for IQ and Autism in Tuberous Sclerosis Complex

Neurology
Neurology
2019English

Tuberous Sclerosis Complex

2020English

Tuberous Sclerosis Complex

2004English

Everolimus for the Treatment of Subependymal Giant Cell Astrocytoma Probably Causing Seizure Aggravation in a Child With Tuberous Sclerosis Complex: A Case Report

Neuropediatrics
MedicineChild HealthNeurologyPediatricsPerinatology
2013English

Everolimus for Epilepsy and Autism Spectrum Disorder in Tuberous Sclerosis Complex: EXIST-3 Substudy in Japan

Brain and Development
Child HealthDevelopmental NeurosciencePerinatologyNeurologyMedicinePediatrics
2019English

Long-Term Treatment of Epilepsy With Everolimus in Tuberous Sclerosis

Neurology
Neurology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy